• The primary endpoint is the incidence of adverse events. [ Time Frame: During treatment with study drug ] [ Designated as safety issue: Yes ]
  

• Secondary endpoints for subjects who underwent PCI included the incidence of adverse events. [ Time Frame: To the end of the post treatment observation period (Day 121) ] [ Designated as safety issue: Yes ]
  
• For subjects who underwent PCI included TIMI major/minor and nonTIMI bleeding, 1st occurrence or certain combo of major adverse cardiac events and death, inhibition of platelet aggregation, and change in hs-CRP, CD40 ligand, & membrane-bound P-selectin. [ Time Frame: During treatment with study drug ] [ Designated as safety issue: Yes ]
  
• Secondary endpoints for subjects who underwent PCI included TIMI major/minor and nonTIMI bleeding, first occurrence or certain combination of major adverse cardiac events and death, and plasma drug concentration. [ Time Frame: To the end of the post treatment observation period (Day 121) ] [ Designated as safety issue: Yes ]
  
• Secondary endpoints for subjects who underwent PCI included "clinically important" bleeding (composite incidence of intracranial bleeding and bleeding requiring blood transfusion and re-hospitalization). [ Time Frame: Discharge from hospital to end of post treatment observation period (Day 121) ] [ Designated as safety issue: Yes ]
  
• Secondary endpoints for subjects who did not undergo PCI included incidence of TIMI major and minor bleeding, nonTIMI bleeding, combination of first occurrence of death and major cardiovascular events, and atherothrombotic ischemic events. [ Time Frame: From the start of administration to the day of discharge ] [ Designated as safety issue: Yes ]
  
• Secondary endpoints for subjects who did not undergo PCI included incidence of adverse events. [ Time Frame: To the end of the post treatment observation period (Day 121) ] [ Designated as safety issue: Yes ]
  
• Secondary endpoints for subjects who did not undergo PCI, but who had CABG, were bleeding, transfusions, and need for subsequent surgery. [ Time Frame: 8 +/- 2 hours after CABG ] [ Designated as safety issue: Yes ]
  
• Secondary endpoints for subjects who did not undergo PCI included change in hs-CRP and expression of CD40 ligand. [ Time Frame: From baseline to the day of discharge ] [ Designated as safety issue: No ]
  
• Secondary endpoints for subjects who did not undergo PCI included clinically significant bleeding. [ Time Frame: From discharge to the end of the post treatment observation period (Day 121) ] [ Designated as safety issue: Yes ]
  

Inclusion Criteria:

• Men and women aged 18 years or more with history of cardiac ischemia related chest discomfort of > 10 minutes duration < 24 hours prior to randomization, and having at least 1 of the following A or B. Subjects who are planned to undergo PCI will be the target subjects.

  • A: Positive biomarkers [Elevated troponin I or CK-MB greater than the site's upper limit of normal (ULN)] at or before registration
  • B: Electrocardiogram (ECG) changes: ST segment depression >= 0.1 mV (>=1 mm), or transient (<30 minutes) ST segment elevation >= 0.1 mV (>=1 mm) in at least 2 contiguous leads
• Willing to give appropriate informed consent and complete all study-related procedures, and able to adhere to dosing and all visit schedules.
• Women of child-bearing potential (all postmenarchal women who are <1 years menopausal or who have not had surgical sterilization or a hysterectomy are considered to be women of child-bearing potential) must agree to use a medically accepted method of contraception while receiving protocol-specified medication, and for 60 days after stopping the medication.

Exclusion Criteria:

• Pregnant and nursing mothers (premenopausal women should have a negative pregnancy test result confirmed before enrollment)
• Any serious illness or any condition that the investigator feels would pose a significant hazard to the subject if investigational therapy were initiated
• known hypersensitivity to any component of the current investigational product;
• Participation in a study of experimental therapy or use of any investigational drug within 30 days before enrollment
• Member of the staff personnel directly involved with this study;
• Family member of the investigational study staff;
• History of a bleeding diathesis, or evidence of active abnormal bleeding within 30 days before enrollment
• History of a hemorrhagic stroke at any time
• Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) while receiving therapy;
• Major surgery within 2 weeks prior to enrollment
• Known platelet count <100,000/mm^3
• Uncontrolled cardiac arrhythmia;
• Known impairment of renal function (serum creatinine >2.0 mg/dL [>176.8 umol/L]), dysproteinemia, nephrotic syndrome, or other renal disease;
• Active or chronic hepatobiliary or hepatic disease, or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) activity more than two times greater than the upper limit of the laboratory reference range
• Anticipated staged PCI
• Concurrent or anticipated treatment with warfarin, factor Xa inhibitor, direct thrombin inhibitor, or antiplatelet agents except aspirin and ticlopidine after enrollment
• Anticipated intracoronary brachytherapy